2026年5月12日 / 美国东部时间下午3:34 / 哥伦比亚广播公司新闻
华盛顿讯——马蒂·马卡里周二辞去美国食品药品监督管理局（FDA）局长一职，此前有多篇报道称，因内部政策分歧，他的任期即将结束。
此次离职前，有报道称FDA的工作议程引发了冲突与紧张。5月6日，FDA批准了电子烟企业格拉斯公司（Glas Inc.）的部分调味电子烟产品，并宣传其旨在限制青少年使用的安全限制措施。据《华尔街日报》报道，这一举措是在特朗普总统施压马卡里批准水果味电子烟后才得以推进的，而马卡里此前一直拒绝批准此类产品。
一位知情人士告诉哥伦比亚广播公司新闻，马卡里因电子烟争议离职，并补充称，这位局长原本不想批准调味电子烟，但被迫屈服于政府其他成员的压力。
哥伦比亚广播公司新闻和其他媒体近日报道称，特朗普总统已批准解雇马卡里的计划。周一，马卡里未出现在椭圆形办公室，与总统及其他顶尖公共卫生官员一同出席孕产妇健康相关活动。
周二下午，总统在白宫南草坪对记者表示，他不想讨论马卡里离职的具体情况，但称他是“很棒的人”，也是“我的朋友”。
“马蒂是个非常优秀的人，但他即将开启新生活，会过得很好，”特朗普说，“他遇到了一些困难。你知道，他是一名出色的医生。他当时确实遇到了一些困难。但他会继续前行，一切都会顺利。”
当天晚些时候，总统在Truth Social平台上发布了马卡里提交辞呈的短信截图。“担任FDA局长是我一生的荣幸。我永远心怀感激，”他写道。
在另一篇帖子中，总统表示，负责食品事务的副局长凯尔·迪亚曼塔斯将临时接任马卡里的职务。
马卡里的辞职是监管FDA的卫生与公众服务部近期的最新一轮人事变动。疫苗主管维奈·普拉萨德——马卡里的盟友——近日第二次离职。
马卡里原计划周三在国会山作证。据一位消息人士透露，迪亚曼塔斯将代替他出席作证。
FDA局长负责监督和监管药品、疫苗以及烟草等产品。FDA监管的消费支出占美国总消费的五分之一，使其成为美国公共卫生领域极具影响力的机构。
曾在特朗普第一任期内担任两年FDA局长的斯科特·戈特利布博士，周日在《与玛格丽特·布伦南会面》节目中表示，这一职位“极具挑战性”，并指出自去年以来FDA的动荡局面有害无益。
“该机构已有多名人员离职。我们看到政治任命人员接管了原本应由职业领导层担任的职位，负责医疗产品中心、药品中心和生物制品中心的工作，”戈特利布说，“因此，我认为这一切累积起来已经对机构造成了损害，而我们上周五看到的持续猜测，我认为只会让情况进一步恶化。”
马卡里是一名英裔美国外科医生，于2025年3月获确认出任FDA局长。他曾是“让美国再次健康”运动的热心支持者，并曾严厉批评联邦政府应对新冠疫情的举措。
电子烟问题并非引发马卡里争议的唯一事件。在保守派和反堕胎团体敦促FDA就堕胎药物米非司酮采取行动后，他们也要求将马卡里赶下台。
2021年，拜登政府允许女性通过远程医疗和邮寄方式获取该药物。大多数终止妊娠的女性都选择药物流产。
去年6月，卫生与公众服务部部长小罗伯特·F·肯尼迪要求马卡里审查米非司酮，以研究“与该药物安全性和有效性相关的真实世界结果和证据”。
去年12月，有报道称马卡里拖延了该研究的推进，此后不久，苏珊·B·安东尼反生命组织等保守派团体呼吁解雇马卡里。
该团体要求立即开展研究，并指责马卡里在该问题上“严重破坏”特朗普和万斯的工作。
“马卡里必须下台，”当时反生命组织苏珊·B·安东尼分会如是说。
克里斯汀·布朗、艾伦·何和塞琳·贡德里博士对本文亦有贡献。
Marty Makary resigns as FDA commissioner after internal tensions
May 12, 2026 / 3:34 PM EDT / CBS News
Washington — Marty Makary resigned as commissioner of the Food and Drug Administration on Tuesday, stepping aside amid a swirl of reports that his tenure was coming to an end over internal policy disagreements.
His departure follows reports of conflict and tension over the FDA’s agenda. On May 6, the FDA approved some flavored e-cigarettes from the vaping company Glas Inc., and touted its safety restrictions to limit use by young people. According to The Wall Street Journal, the move came only after Mr. Trump pressured Makary to approve the fruit-flavored vapes, which he had been refusing to do.
One source familiar with the matter told CBS News that Makary is leaving over the e-cigarette dispute, adding that the commissioner didn’t want to approve the flavored varieties but had been forced to by other members of the administration.
CBS News and other outlets had reported in recent days that President Trump had signed off on a plan to fire him. Makary didn’t appear Monday in the Oval Office alongside the president and other top public health officials for an event on maternal health.
Speaking to reporters on the South Lawn of the White House on Tuesday afternoon, the president said he did not want to discuss the circumstances of Makary’s departure, but called him a “great guy” and a “friend of mine.”
“Marty’s a terrific guy, but he’s going to go on and he’s going to lead a good life,” Mr. Trump said. “He was having some difficulty. You know, he’s a great doctor. And he was having some difficulty. But he’s going to go on and he’s going to do well.”
Later in the afternoon, the president posted to Truth Social a screenshot of a text from Makary submitting his resignation. “It’s been the honor of a lifetime to serve as your FDA Commissioner. I am forever grateful,” he wrote.
In a separate post, the president said that Kyle Diamantas, the deputy commissioner for food, would step into Makary’s role on an acting basis.
Makary’s resignation is the latest shakeup within the Department of Health and Human Services, which oversees the FDA. Vaccines chief Vinay Prasad — an ally of Makary — recently departed for a second time.
Makary was expected to testify on Capitol Hill on Wednesday. Diamantas is expected to testify in Makary’s place, according to one source.
The FDA commissioner is responsible for overseeing and regulating drugs, vaccines and tobacco, among other things. The FDA regulates one-fifth of consumer spending in the U.S., making it a powerful agency within American public health.
Dr. Scott Gottlieb, who served as FDA commissioner for two years during Mr. Trump’s first term, told “Face the Nation with Margaret Brennan” on Sunday that the role is a “very difficult job,” and noted the upheaval at the FDA since last year has been detrimental.
“There’s been a lot of departures from the agency. You’ve seen political appointees take over what are typically career leadership positions, running the medical product centers, the drug center and the biologics center,” Gottlieb said. “So, I think cumulatively, that’s taken a toll on the agency, and this continued speculation that we saw on Friday, I think is just going to be another step downward.”
Makary, a British-American surgeon, was confirmed to lead the FDA in March 2025. He was an avid supporter of the Make America Healthy Again movement and had been highly critical of the federal response to the COVID-19 pandemic.
The vaping issue wasn’t the only one that caused friction for Makary. Conservatives and anti-abortion groups also sought Makary’s ouster after pressing the FDA to take action on the abortion drug mifepristone.
In 2021, the Biden administration made it possible for women to receive the pills via telehealth and by mail. The majority of women who terminate pregnancies do so through medication abortions.
Last June, Health and Human Services Secretary Robert F. Kennedy Jr. asked Makary to review mifepristone to examine “real-world outcomes and evidence, relating to the safety and efficacy of the drug.”
In December, there were reports he had slow-walked the study, and soon afterward, Susan B. Anthony Pro-Life America and other conservatives called for Makary’s firing.
The group called for an immediate study and went on to accuse Makary of “severely undermining” Mr. Trump and Vance on the issue.
“Makary must go,” SBA Pro-Life America said at the time.
Kristin Brown, Alan He and Dr. Céline Gounder contributed to this report.
发表回复